Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells
3/22/2021
A recent publication in Science Immunology by the laboratory of Darrell Irvine at Massachusetts Institute of Technology describes a new approach to mucosal vaccine development. They have designed an “amph-vaccine” formulation designed for delivery to the lungs by inhalation that is able to elicit a strong tissue-resident memory T cell response in the lung. Many viruses infect their hosts through mucosal surfaces such as the lining of the respiratory tract. The new amph-vaccine strategy can create an army of T cells that are ready and waiting at those surfaces, offering a quicker response to viral invaders.
Here is a link to a summary of the work written by MIT with a catchy title of "Time to Face the Mucus." https://ki.mit.edu/news/2021/time-face-mucus
The full MIT press summary can be found at https://news.mit.edu/2021/vaccination-inhalation-0319.
A recent publication in Science Immunology by the laboratory of Darrell Irvine at Massachusetts Institute of Technology describes a new approach to mucosal vaccine development.
